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Duct-narrowing chronic pancreatitis without immunoserological 
abnormality: comparison with duct-narrowing chronic pancreatitis with 
positive serological evidence and its clinical management. 
 
N. Sawabu, T. Wakabayashi, Y. Satomura, H. Watanabe, Y. Motoo 
 
 We reviewed the clinical features and clinical course of patients with duct-narrowing chronic pancreatitis 
who were negative for immunoserological test results (n=16) in comparison with the findings for 
serological test-positive patients (n=20) in order to determine an adequate treatment for those who had 
typical morphology of autoimmune pancreatitis in the absence of immunoserological abnormality. No 
significant differences were found between the two groups of patients in clinical profiles including 
associated autoimmune-related diseases, pancreatic histology, and response to steroid therapy. Of the 
seronegative patients, eight  patients who showed an improvement in narrowing of the main pancreatic 
duct with steroid therapy and three who did no show an improvement or who relapsed after surgical 
resection without this therapy had stenosis of the common bile duct with increased levels of serum 
hepatobiliary enzymes, except for two patients with affected sites limited to the body or tail of the gland. 
For the remaining five patients, who showed an improvement in pancreatic duct changes or long-term 
remission after surgery without steroid administration, normal biochemistry test results for liver functions 
were obtained, with no abnormal cholangiographic findings in the 3 patients examined.  
 Duct-narrowing chronic pancreatitis without immunoserological abnormality overlaps in clinical features 
with that fulfilling the immunoserological criteria for a diagnosis of autoimmune pancreatitis. In particular, 
the disease with bile duct involvement should be treated clinically as autoimmune pancreatitis, for which 
steroid therapy is recommended, even if an autoimmune mechanism is not demonstrated serologically. 
 
Table. Comparison of clinicopathologic findings for seropositive and seronegative DNCP patients 
 Clinicopathologic finding seropositive seronegative P value 
  (n=20) (n=16)  
Sex (male/female) 17/3 10/6 p＞0.10 
Age (mean±SD; yr) 62.9±10.0 57.6±13.9 p=0.20 
Location (diffuse/focal) 17/3 12/4 p＞0.90 
DM 12 (60%) 6 (38%) p＞0.25 
Extrabilopancreatic autoimmune- 6 (30%) 3 (19%) p＞0.50 
related disease  
Jaundice 11 (55%) 5 (31%) p＞0.25 
Upper abdominal pain 4 (20%) 7 (44%) p＞0.10 
Increased cholestatic enzymes 15 (75%) 9 (56%) p＞0.25 
Increased pancreatic enzymes 10 (50%) 13 (81%) p＞0.10 
CBD  stenosis 18/19 (95%) 9/12 (75%) p＞0.25 
Dense inflammatory cell infiltration 7/8 (88%) 4/6 (67%)  p＞0.75 
Effective steroid therapy  14/15 (93%) 8/8 (100%) p＞0.50 
DNCP, duct-narrowing chronic pancreatitis; DM, diabetes mellitus; CBD, common bile duct 
 
